Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study findings from University of Pittsburgh broaden understanding of breast cancer
June 25th, 2009
According to a study from the United States, "Postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors (Als) are at risk for accelerated bone loss and subsequent fractures. The ongoing Zometa-Femora Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of zoledronic acid in preventing such bone loss." "In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years. Delayed-start ZA was administered if the lumbar spine (LS) or total hip (TH) T score...
Source: Women's Health Weekly (2009-06-25)
|
